AbbVie Inc. (BCBA:ABBV)

Argentina flag Argentina · Delayed Price · Currency is ARS
33,020
+160 (0.49%)
Feb 10, 2026, 4:57 PM BRT
Market Cap552.87T +75.4%
Revenue (ttm)88.77T +8.6%
Net Income6.13T -1.2%
EPS3,425.30 -1.3%
Shares Outn/a
PE Ratio90.14
Forward PE15.22
Dividend544.57 (1.65%)
Ex-Dividend DateJan 16, 2026
Volume454
Average Volume1,622
Open33,080
Previous Close32,860
Day's Range32,540 - 33,260
52-Week Range18,750 - 38,540
Betan/a
RSI46.70
Earnings DateFeb 4, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]

Sector Healthcare
Founded 2012
Employees 55,000
Stock Exchange Buenos Aires Stock Exchange
Ticker Symbol ABBV
Full Company Profile

Financial Performance

In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.23 billion, a decrease of -0.28%.

Financial numbers in USD Financial Statements